Skip to content
Home/Companies/Biotech/Edgewise Therapeutics

Edgewise Therapeutics

Biotech·US·Active·7yr hold
Entry
2019
Hold
7yr
Status
Active

Who owns Edgewise Therapeutics?

Edgewise Therapeutics is currently owned by Novo Holdings through Novo Holdings Venture Investments (1999 vintage), since 2019.

Hand-verified · updated 2026-08-18

Novo Holdings
Investor
Novo Holdings
Novo Holdings Venture Investments · 1999 · VC

Key facts

HQUnited States
SectorBiotech
StatusActive

More from Novo Holdings Venture Investments

Other portfolio companies in the same fund.

Claris Biotherapeutics
Active
BiotechUS· 2026
Windward Bio AG
Active
BiotechSwitzerland· 2026
AnaCardio
Active
BiotechSweden· 2025
Expedition Therapeutics
Active
BiotechUS· 2025
KIVU Bioscience
Active
BiotechUS· 2025
Asceneuron
Active
BiotechSwitzerland· 2024

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Aldevron
Aldevron
Active
TA AssociatesUS
Antiverse
Antiverse
Active
Future Planet CapitalUK
CellCentric
CellCentric
Active
Future Planet CapitalUK
Crescendo Biologics
Crescendo Biologics
Active
Future Planet CapitalUK
Cytox Group
Exited 2024
Future Planet CapitalUK
Elkedonia
Elkedonia
Active
Capital Grand EstFrance
Track Edgewise Therapeutics

Save this record to your watchlist and pick up your research where you left off. No spam.

Create free account

Who could buy Edgewise Therapeutics?

7 strategic and 113financial buyers match this company's sector and geography profile, ranked from verified European deal history.

Find likely buyers

Get the full record on Edgewise Therapeutics.

Free. No credit card. 30 seconds. Exit buyers and MOIC on Pro.

Hand-checked deal notes on this investment
Save this company to your watchlist
Exit buyers and MOIC on realized deals (Pro)
or
Continue with email

Already a member? Sign in

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue